Membrane Fusion Liposomes Deliver Antifibrotic and Chemotherapeutic Drugs Sequentially to Enhance Tumor Treatment Efficacy by Reshaping Tumor Microenvironment
Advanced Healthcare Materials · 2024-08 · 13 (20)
DOI: 10.1002/adhm.202400219 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 11.05.2024. Verfasst von Nan Jia und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province, 110016, China. Hauptthemen laut MEDLINE: Liposomes, Tumor Microenvironment, Doxorubicin. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
The intricate tumor microenvironment in triple‐negative breast cancer (TNBC) hampers chemotherapy and immunotherapy efficacy due to dense extracellular matrix (ECM) by tumor‐associated fibroblasts (TAFs). Nanoparticle‐based therapies, especially “all‐in‐one” nanoparticles, have shown great potential in combined drug delivery strategies to reshape the tumor microenvironment and enhance therapeutic efficiency. However, these “all‐in‐one” nanoparticles suffer from limitations in targeting different target cells, uncontrollable dosing ratio, and disregarding the impact of delivery schedules. This study prepared cell membrane fusion liposomes (TAFsomes and CCMsomes) to load FDA‐approved antifibrotic drug pirfenidone (PFD/TAFsomes) and antitumor drug doxorubicin (DOX/CCMsomes). These liposomes can specifically target TAFs cells and tumor cells, and combined administration can effectively inhibit TAFs activity, reshape the tumor microenvironment (TME), and significantly enhance the tumor chemotherapy efficacy. Combined drug delivery defeats “all‐in‐one” liposomes (DOX/PFD/Liposomes, DOX/PFD/TAFsomes, and DOX/PFD/CCMsomes) by flexibly adjusting the drug delivery ratio. Moreover, an asynchronous delivery strategy that optimizes the administration schedule not only further improves the therapeutic effect, but also amplifies the effectiveness of α‐PD‐L1 immunotherapy by modulating the tumor immune microenvironment. This delivery strategy provides a personalized treatment approach with clinical translation potential, providing new ideas for enhancing the therapeutic effect against solid tumors such as TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang, Liaoning Province, 110016, China.
- Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL, 36849, USA.
ORCID-Profile: Haiyang Hu
Zitieren
APA
Jia, N., Wang, Q., Li, W., Chen, D., & Hu, H. (2024). Membrane Fusion Liposomes Deliver Antifibrotic and Chemotherapeutic Drugs Sequentially to Enhance Tumor Treatment Efficacy by Reshaping Tumor Microenvironment. Advanced Healthcare Materials, 13(20). https://doi.org/10.1002/adhm.202400219
Vancouver
Jia N, Wang Q, Li W, Chen D, Hu H. Membrane Fusion Liposomes Deliver Antifibrotic and Chemotherapeutic Drugs Sequentially to Enhance Tumor Treatment Efficacy by Reshaping Tumor Microenvironment. Advanced Healthcare Materials. 2024;13(20). doi:10.1002/adhm.202400219
BibTeX
@article{Jia2024,
author = {Jia, Nan and Wang, Qi and Li, Wenpan and Chen, Dawei and Hu, Haiyang},
title = {Membrane Fusion Liposomes Deliver Antifibrotic and Chemotherapeutic Drugs Sequentially to Enhance Tumor Treatment Efficacy by Reshaping Tumor Microenvironment},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {20},
doi = {10.1002/adhm.202400219}
}
EUVIMED